Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of “Buy” from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $26.60.

A number of brokerages recently issued reports on ATXS. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Wedbush reiterated an “outperform” rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS opened at $5.70 on Friday. The business has a 50 day simple moving average of $6.81 and a 200 day simple moving average of $9.15. Astria Therapeutics has a 52 week low of $5.68 and a 52 week high of $14.04. The stock has a market cap of $321.67 million, a price-to-earnings ratio of -2.73 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. On average, analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

Hedge Funds Weigh In On Astria Therapeutics

Several large investors have recently made changes to their positions in ATXS. Charles Schwab Investment Management Inc. raised its stake in Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after purchasing an additional 189,727 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Astria Therapeutics during the 3rd quarter worth about $613,000. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the last quarter. Barclays PLC lifted its stake in shares of Astria Therapeutics by 70.5% in the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after buying an additional 38,321 shares during the period. Finally, Vestal Point Capital LP grew its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.